Table 2.
Comparison of patient characteristics with and without Staphylococcus aureus endocarditis
| Variable | No S. aureus (n=36) | S. aureus (n=20) | P value |
| Patient/diagnosis data | |||
| Age at cancer diagnosis (years) | 52.9±16.82 | 55.25±15.27 | 0.8844 |
| Age at endocarditis diagnosis (years) | 60.08±15.59 | 58.57±15.16 | 0.4069 |
| Time from cancer diagnosis to endocarditis diagnosis (months) | 86.6±146.12 | 40.31±51.54 | 0.5158 |
| Sex | 0.5478 | ||
| Male | 21 (58.3%) | 10 (50%) | |
| Female | 15 (41.7%) | 10 (50%) | |
| Race/ethnicity | 0.61 | ||
| Non-black (white/other) | 24 (66.7%) | 12 (60%) | |
| Black | 12 (33.3%) | 8 (40%) | |
| Comorbidities | |||
| Diabetes mellitus | 10 (27.8%) | 3 (15%) | 0.3392 |
| HIV | 0 (0%) | 1 (5) | 0.3455 |
| Congestive heart failure | 5 (13.9%) | 2 (10%) | 1 |
| Chronic kidney disease | 6 (16.7%) | 4 (20%) | 0.7234 |
| Oncologic data | |||
| Type of cancer | 0.798 | ||
| Haematological cancer | 12 (33.3%) | 6 (30%) | |
| Solid cancer | 24 (66.7%) | 14 (70%) | |
| Cancer status | 0.0963 | ||
| Cancer in remission | 10 (27.8%) | 10 (50%) | |
| Active cancer | 26 (72.2%) | 10 (50%) | |
| Active chemotherapy treatment | 22 (61.1%) | 12 (60%) | 0.935 |
| Steroid treatment | 3 (8.3%) | 3 (15%) | 0.4055 |
| Invasive procedures/endocarditis risk factors | |||
| Preexisting valvular heart disease | 8 (22.2%) | 0 (0%) | 0.0405 |
| Pacemaker presence | 3 (8.3%) | 1 (5%) | 1 |
| Bone marrow treatment/procedure | 8 (22.2%) | 2 (10%) | 0.3036 |
| Dental extraction | 0 (0%) | 2 (10%) | 0.1234 |
| Cystoscopy | 0 (0%) | 2 (10%) | 0.1234 |
| Upper GI endoscopy | 1 (2.8%) | 2 (10%) | 0.2879 |
| Lower GI endoscopy | 1 (2.8%) | 1 (5%) | 1 |
| Indwelling catheter/line | 10 (27.8%) | 10 (50%) | 0.0742 |
| Lab values | |||
| Haemoglobin (g/dL) | 9.96±2 | 10.24±2.04 | 0.6772 |
| White blood cell count (K/µL) | 11.29±13.68 | 14.68±11 | 0.0442 |
| Platelets (K/µL) | 163.12±120.13 | 205.70±141.10 | 0.2865 |
| Blood urea nitrogen (mg/dL) | 26.47±19.26 | 25.85±18.63 | 0.8019 |
| Creatinine (mg/dL) | 1.43±1.4 | 1.25±0.74 | 0.7506 |
| Alanine aminotransferase (U/L) | 59.72±111.25 | 47.3±45.82 | 0.5156 |
| Aspartate aminotransferase (U/L) | 60.63±85.59 | 44.05±31.28 | 0.8359 |
| Total bilirubin (mg/dL) | 0.97±1.15 | 1.48±3.09 | 0.374 |
| Site of involvement | |||
| Aortic valve | 13 (36.1%) | 7 (35%) | 0.9337 |
| Mitral valve | 17 (47.2%) | 6 (30%) | 0.2094 |
| Tricuspid valve | 6 (16.7%) | 3 (15%) | 1 |
| Pacemaker lead | 1 (2.8%) | 1 (5%) | 1 |
GI, gastrointestinal.